Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

Small cell lung cancer (SCLC) accounts for about 15% of lung cancer cases and is categorized into limited and extensive stages. Treatment options include radiation, chemotherapy, and immunotherapy ...

For patients with stage IA non-small cell lung cancer (NSCLC), lung resections, including lobectomy and segmentectomy, are associated with improved long-term survival compared with wedge resection, ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy. The Food and Drug Administration (FDA) grants Priority Review to applications for ...